Watch now to hear from TAVR trailblazers

Leading physicians discuss the success of TAVR treatment for their patients and what’s possible from here.

Innovating together, with 25,000+ patients studied around the world.

Scroll / swipe side to side to review timeline

*The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure) and multiple pre-specified secondary endpoints.

Learn more

Find the latest data, training programs, and resources designed to optimize patient care and increase efficiencies.

References:   1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.